ChemDiv Expands CMC Services for Ratutrelvir Development
ChemDiv, a premier global provider of integrated drug discovery solutions, is excited to announce the expansion of its Chemistry, Manufacturing and Controls (CMC) services collaboration to enhance the clinical development of ratutrelvir. This innovative oral antiviral treatment shows significant potential for COVID-19 and is currently progressing into Phase 2 clinical trials.
Progress in Clinical Development
This extension follows recent advancements by Traws Pharma, Inc. (NASDAQ: TRAW), which has initiated dosing of the first patient in its Phase 2 studies for ratutrelvir. The announcement comes with an anticipation for top-line data expected soon, further establishing the trajectory of this promising therapeutic agent.
About Ratutrelvir
Ratutrelvir is a novel Main protease (Mpro/3CL) inhibitor, distinguished by its absence of ritonavir, setting it apart from existing COVID-19 treatments. It was meticulously developed by ChemDiv's adept medicinal chemistry and virology teams. By utilizing advanced drug design methods, ratutrelvir achieves exceptional potency against a diverse array of native and resistant SARS-CoV-2 strains.
The Benefits of Ratutrelvir
Significantly, ratutrelvir also features a streamlined 10-day treatment regimen, which eliminates the need for co-administration of ritonavir—an element that often complicates patient eligibility due to potential drug-drug interactions associated with existing therapies. The unique characteristics make ratutrelvir a compelling candidate in the fight against COVID-19.
Collaborative Efforts in Drug Development
ChemDiv's collaboration extends to multiple facets of the drug development process, focusing on:
- CMC process research and scale-up for Active Pharmaceutical Ingredient (API) and Drug Product (DP) necessary for conducting non-GLP and GLP studies,
- Medicinal chemistry support to develop backup series,
- Translational pharmacology services that leverage computational modeling alongside wet-lab validation,
- Clinical pharmacology consulting aimed at refining dosing strategies for Phase 2 and subsequent trials.
Endorsement from ChemDiv Leadership
Ilya Baimetov, COO at ChemDiv, expressed pride in the ongoing efforts to advance ratutrelvir from discovery through clinical development. He highlighted the powerful synergy of ChemDiv's medicinal chemistry expertise with cutting-edge tools provided by Molsoft and Expert Systems, a collaboration that positions ratutrelvir as a potential best-in-class therapeutic option.
Evaluating Clinical Efficacy
Currently, ratutrelvir is undergoing evaluation in two distinct Phase 2 clinical studies. One of these trials is a non-inferiority approach comparing ratutrelvir with other leading treatments like PAXLOVID® in patients newly diagnosed with COVID-19. The second study addresses PAXLOVID®-ineligible patients, a demographic that often lacks viable treatment options.
Research and Development Overview
Phase 1 studies have showcased that ratutrelvir maintains plasma levels that are approximately 13 times higher than the EC??, while also adhering to a 10-day daily dosing schedule without the inclusion of ritonavir. This innovative approach could reduce the potential for viral rebound and the associated risks of Long COVID.
About Expert Systems, Inc.
Expert Systems has proven to be an invaluable partner, utilizing its hybrid AI-based platform to streamline the preclinical drug discovery process. This collaboration ensures that ratutrelvir continues to meet stringent safety and regulatory standards, essential for its advancement into the later stages of clinical development.
About Traws Pharma, Inc.
Traws Pharma (NASDAQ: TRAW) is committed to developing cutting-edge biopharmaceutical therapies aimed at tackling severe health concerns posed by respiratory viral illnesses. The company is pioneering the advancement of oral antiviral agents that demonstrate potent efficacy against challenging or resistant viral strains, exemplified by ratutrelvir for COVID-19.
About ChemDiv
ChemDiv stands out as a holistic discovery partner from target to clinic. With an extensive library exceeding 12 million screening compounds available and a repertoire of over 70,000 building blocks, ChemDiv provides unparalleled resources for drug design. Their comprehensive services encompass custom medicinal chemistry, AI-driven computational pharmacology, and robust support throughout the drug development process.
Frequently Asked Questions
What is ratutrelvir?
Ratutrelvir is an oral antiviral treatment being developed for COVID-19, targeting the SARS-CoV-2 main protease without the need for ritonavir.
Who is ChemDiv?
ChemDiv is a global leader in integrated drug discovery solutions, providing support for medicinal chemistry, CMC, and pharmacology.
What role does Traws Pharma play?
Traws Pharma is advancing the clinical development of ratutrelvir and other antiviral agents aimed at respiratory diseases.
Why is ratutrelvir significant?
Its unique formulation allows for a simplified treatment regimen and reduced drug interactions, making it a promising option for COVID-19 therapy.
How is ChemDiv ensuring effective development of ratutrelvir?
ChemDiv combines advanced medicinal chemistry capabilities with cutting-edge AI tools to optimize the drug development process across various phases.
